Anti-inflammatory effects of WFS1 in pancreatic beta-cells
Shuntaro MorikawaiD, Lindsey Blacher, Chinyere Onwumere, Fumihiko UranoiD
Abstract
Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, optic nerve atrophy, hearing loss, diabetes insipidus, and progressive neurodegeneration. Pathogenic variants in the WFS1 gene are the main causes of Wolfram syndrome. WFS1 encodes a transmembrane protein localized to the endoplasmic reticulum (ER) and regulates the unfolded protein response (UPR). Loss of function of WFS1 leads to dysregulation of insulin production and secretion, ER calcium depletion, and cytosolic calpains activation, resulting in activation of apoptotic cascades. Although the terminal UPR has been shown to induce inflammation that accelerates {beta}-cell dysfunction and death in diabetes, the contribution of {beta}-cell inflammation to the development of diabetes in Wolfram syndrome has not been fully understood. Here we show that WFS1-deficiency enhances the gene expression of inflammatory cytokines and chemokines, leading to cytokine-induced ER-stress and cell death in pancreatic {beta}-cells. PERK and IRE1 pathways mediate high glucose-induced inflammation in a {beta}-cell model of Wolfram syndrome. M1-macrophage infiltration and hypervascularization are seen in the pancreatic islets of Wfs1 whole-body knockout mice, demonstrating that WFS1 regulates anti-inflammatory responses in {beta}-cells. Our results demonstrate that inflammation plays an essential role in the progression of {beta}-cell death and diabetes in Wolfram syndrome and reveal that the pathways involved in ER stress-mediated inflammation provide potential therapeutic targets for the treatment of Wolfram syndrome.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Liraglutide treatment reverses unconventional cellular defects in induced pluripotent stem cell-derived β cells harboring a partially functional WFS1 variant
Silvia Torchio, Gabriel Siracusano, … Lorenzo Piemonti·DiabetesPeer-reviewed·Apr 9, 2025
- A WFS1 variant disrupting acceptor splice site uncovers the impact of alternative splicing on β cell apoptosis in a patient with Wolfram syndrome.
Raniero Chimienti, Silvia Torchio, … Lorenzo Piemonti·bioRxiv·Dec 29, 2023
- Insulin secretion deficits in a Prader-Willi syndrome β-cell model are associated with a concerted downregulation of multiple endoplasmic reticulum chaperones
Erik Koppes, Marie A. Johnson, … Robert D. Nicholls·PLoS GeneticsPeer-reviewed·Apr 17, 2023
- MCT1-dependent energetic failure and neuroinflammation underlie optic nerve degeneration in Wolfram syndrome mice
Greta Rossi, Gabriele Ordazzo, … Vania Broccoli·eLifePeer-reviewed·Jan 16, 2023
- A Phase 1b/2a Clinical Trial of Dantrolene Sodium in Patients with Wolfram Syndrome
Damien Abreu, Stephen Stone, … Fumihiko Urano·JCI InsightPeer-reviewed·Jun 29, 2021
- A deep phenotyping study in mouse and iPSC models to understand the role of oligodendroglia in optic neuropathy in Wolfram syndrome
K. Ahuja, Marjan Vandenabeele, … Lies De Groef·Acta Neuropathologica CommunicationsPeer-reviewed·Aug 28, 2024